Pertuzumab plus trastuzumab (P+T) in patients (pts) with solid tumors with ERBB2or ERBB3amplification (amp) or mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.,Journal of Clinical Oncology

当前位置： X-MOL 学术 › J. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Pertuzumab plus trastuzumab (P+T) in patients (pts) with solid tumors with ERBB2or ERBB3amplification (amp) or mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology ( IF 42.1 ) Pub Date : 2024-05-29 , DOI: 10.1200/jco.2024.42.16_suppl.3142
Elie G. Dib ₁ , Michael Rothe ₂ , Pam K. Mangat ₂ , Elizabeth Garrett-Mayer ₂ , Eugene Ahn ₃ , Ajjai Shivaram Alva ₄ , Navid Hafez ₅ , Evthokia Hobbs ₆ , Mehmet Akce ₇ , Deepti Behl ₈ , Carmen Julia Calfa ₉ , Timothy Lewis Cannon ₁₀ , Meredith McKean ₁₁ , Funda Meric-Bernstam ₁₂ , Ramya Thota ₁₃ , Allison Paige Watson ₁₄ , Kathleen J Yost ₁₅ , Abby Gregory ₂ , Susan Halabi ₁₆ , Richard L. Schilsky ₂

Affiliation

Michigan Cancer Research Consortium, Ypsilanti, MI
ASCO, Alexandria, VA
City of Hope - Chicago, Zion, IL
University of Michigan Rogel Comprehensive Cancer Center, Ann Arbor, MI
The Angeles Clinic, Los Angeles, CA
Providence Cancer Institute, Portland, OR
Division of Hematology and Oncology, Department of Medicine, O’Neal Comprehensive Cancer Center of University of Alabama at Birmingham, Heersink School of Medicine, Birmingham, AL
Sutter Sacramento Medical Center, Sacramento, CA
Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL
Inova Schar Cancer Institute, Fairfax, VA
Sarah Cannon Research Institute, Nashville, TN
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
Intermountain Healthcare, Murray, UT
Sanford Health, Sioux Falls, SD
Cancer Research Consortium of West Michigan, Grand Rapids, MI
Duke University School of Medicine, Durham, NC

Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3142-3142, June 2024.

中文翻译：

帕妥珠单抗加曲妥珠单抗 (P+T) 治疗具有 ERBB2 或 ERBB3 扩增 (amp) 或突变 (mut) 的实体瘤患者 (pts)：来自靶向药物和分析利用登记 (TAPUR) 研究的结果。

《临床肿瘤学杂志》，第 42 卷，第 16 期_suppl，第 3142-3142 页，2024 年 6 月。

更新日期：2024-05-30

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南